Appeal of Physician-Dispensed Abiraterone and Enzalutamide for mCRPC Grows Stronger
With novel treatments such as abiraterone acetate (Zytiga) and enzalutamide (Xtandi) emerging and financial challenges of diminished reimbursement faced by urology practices mounting, urology groups are beginning to offer in-office dispensing to their metastatic castration-resistant prostate cancer (mCRPC) patients.
In-office dispensing can meet patient needs by enhancing patient care and outcomes, as well as provides practices with another service line and revenue stream, said Karen K. Kellogg, PharmD, director business solutions, VitalSource GPO, Specialty Solutions, during a breakout session at the 2015 LUGPA Annual Meeting…
